TAVIPILOT Soft
AI Guidance for Transcatheter Aortic Valve Implantation (TAVI)
CommercialFDA Cleared; First Clinical Use
Key Facts
Indication
AI Guidance for Transcatheter Aortic Valve Implantation (TAVI)
Phase
Commercial
Status
FDA Cleared; First Clinical Use
Company
About Carvolix
Carvolix, founded by Truffle Capital in 2026, is a unified entity created from the merger of Caranx Medical, Artedrone, and Affluent Medical, with the mission to expand patient access to complex valve and stroke procedures. The company has achieved key milestones, including FDA clearance and first-in-human use of its TAVIPILOT AI software and robotic system for transcatheter aortic valve implantation (TAVI). Its strategy leverages a synergistic platform of AI, robotics, and next-generation implants to empower the large, underutilized base of interventional cardiologists, aiming to transform the catheterization lab into an efficient, 'autopilot'-enabled environment.
View full company profile